Skip to main content
Top
Published in: Familial Cancer 4/2009

01-12-2009

Molecular study of CEPBA in familial hematological malignancies

Authors: R. El Abed, V. Bourdon, L. Huiart, F. Eisinger, A. Khelif, M. Frenay, P. Gesta, L. Demange, H. Dreyfus, V. Bonadona, C. Dugast, H. Zattara, L. Faivre, T. Noguchi, R. Sauvan, Z. Soua, H. Sobol

Published in: Familial Cancer | Issue 4/2009

Login to get access

Abstract

Familial aggregation in patients with several haematological malignancies has been described, but the genetic basis for this familial clustering is not known. Few genes predisposing to familial haematological malignancies have been identified, among which RUNX1 and CEBPA have been described as predisposing genes to acute myeloid leukemia (AML). Recent studies on RUNX1 suggest that germline mutations in this gene predispose to a larger panel of familial haematological malignancies than AML. In order to strengthen this hypothesis, we have screened CEBPA for germline mutations in several families presenting aggregation of hematological malignancies (including chronic or acute, lymphoid or myeloid leukemias, Hodgkin’s or non Hodgkin’s lymphomas, and myeloproliferative or myelodysplastic syndromes) with or without solid tumours. Although no deleterious mutations were found, we report two novel and rare variants of uncertain significance. In addition, we confirm that the in frame insertion c.1175_1180dup (p.P194_H195dup) is a germline polymorphism.
Literature
1.
go back to reference Fuchs O (2007) Growth-inhibiting activity of transcription factor C/EBPalpha, its role in haematopoiesis and its tumour suppressor or oncogenic properties in leukaemias. Folia Biol (Praha) 53(3):97–108 Fuchs O (2007) Growth-inhibiting activity of transcription factor C/EBPalpha, its role in haematopoiesis and its tumour suppressor or oncogenic properties in leukaemias. Folia Biol (Praha) 53(3):97–108
2.
go back to reference Frohling S, Schlenk RF, Stolze I et al (2004) CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 22(4):624–633CrossRefPubMed Frohling S, Schlenk RF, Stolze I et al (2004) CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 22(4):624–633CrossRefPubMed
3.
go back to reference Zhang DE, Zhang P, Wang ND, Hetherington CJ, Darlington GJ, Tenen DG (1997) Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci USA 94(2):569–574CrossRefPubMed Zhang DE, Zhang P, Wang ND, Hetherington CJ, Darlington GJ, Tenen DG (1997) Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci USA 94(2):569–574CrossRefPubMed
4.
go back to reference Wouters BJ, Lowenberg B, Erpelinck-Verschueren CA, van Putten WL, Valk PJ, Delwel R (2009) Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 113(13):3088–3091CrossRefPubMed Wouters BJ, Lowenberg B, Erpelinck-Verschueren CA, van Putten WL, Valk PJ, Delwel R (2009) Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 113(13):3088–3091CrossRefPubMed
5.
go back to reference Fuchs O, Provaznikova D, Kocova M et al (2008) CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin’s lymphoma. Blood Cells Mol Dis 40(3):401–405CrossRefPubMed Fuchs O, Provaznikova D, Kocova M et al (2008) CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin’s lymphoma. Blood Cells Mol Dis 40(3):401–405CrossRefPubMed
6.
go back to reference Smith ML, Cavenagh JD, Lister TA, Fitzgibbon J (2004) Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med 351(23):2403–2407CrossRefPubMed Smith ML, Cavenagh JD, Lister TA, Fitzgibbon J (2004) Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med 351(23):2403–2407CrossRefPubMed
7.
go back to reference Nanri T, Uike N, Kawakita T et al (2006) A pedigree harboring a germ-line N-terminal C/EBP{alpha} mutation and development of acute myeloblastic leukemia with a somatic C-terminal C/EBP{alpha} mutation. Blood 108(11):1916 Nanri T, Uike N, Kawakita T et al (2006) A pedigree harboring a germ-line N-terminal C/EBP{alpha} mutation and development of acute myeloblastic leukemia with a somatic C-terminal C/EBP{alpha} mutation. Blood 108(11):1916
8.
go back to reference Pabst T, Eyholzer M, Haefliger S, Schardt J, Mueller BU (2008) Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia. J Clin Oncol 26(31):5088–5093CrossRefPubMed Pabst T, Eyholzer M, Haefliger S, Schardt J, Mueller BU (2008) Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia. J Clin Oncol 26(31):5088–5093CrossRefPubMed
9.
go back to reference Sellick GS, Spendlove HE, Catovsky D, Pritchard-Jones K, Houlston RS (2005) Further evidence that germline CEBPA mutations cause dominant inheritance of acute myeloid leukaemia. Leukemia 19(7):1276–1278CrossRefPubMed Sellick GS, Spendlove HE, Catovsky D, Pritchard-Jones K, Houlston RS (2005) Further evidence that germline CEBPA mutations cause dominant inheritance of acute myeloid leukaemia. Leukemia 19(7):1276–1278CrossRefPubMed
10.
go back to reference Renneville A, Mialou V, Philippe N et al (2009) Another pedigree with familial acute myeloid leukemia and germline CEBPA mutation. Leukemia 23(4):804–806CrossRefPubMed Renneville A, Mialou V, Philippe N et al (2009) Another pedigree with familial acute myeloid leukemia and germline CEBPA mutation. Leukemia 23(4):804–806CrossRefPubMed
11.
go back to reference Preudhomme C, Renneville A, Bourdon V et al (2009) High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. Blood 113(22):5583–5587CrossRefPubMed Preudhomme C, Renneville A, Bourdon V et al (2009) High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. Blood 113(22):5583–5587CrossRefPubMed
12.
go back to reference Lin LI, Chen CY, Lin DT et al (2005) Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clin Cancer Res 11(4):1372–1379CrossRefPubMed Lin LI, Chen CY, Lin DT et al (2005) Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clin Cancer Res 11(4):1372–1379CrossRefPubMed
13.
go back to reference Biggio V, Renneville A, Nibourel O et al (2008) Recurrent in-frame insertion in C/EBPalpha TAD2 region is a polymorphism without prognostic value in AML. Leukemia 22(3):655–657CrossRefPubMed Biggio V, Renneville A, Nibourel O et al (2008) Recurrent in-frame insertion in C/EBPalpha TAD2 region is a polymorphism without prognostic value in AML. Leukemia 22(3):655–657CrossRefPubMed
14.
go back to reference Resende C, Regalo G, Duraes C, Carneiro F, Machado JC (2007) Genetic changes of CEBPA in cancer: mutations or polymorphisms? J Clin Oncol 25(17):2493–2494 (author reply 4–5)CrossRefPubMed Resende C, Regalo G, Duraes C, Carneiro F, Machado JC (2007) Genetic changes of CEBPA in cancer: mutations or polymorphisms? J Clin Oncol 25(17):2493–2494 (author reply 4–5)CrossRefPubMed
15.
go back to reference Wouters BJ, Louwers I, Valk PJ, Lowenberg B, Delwel R (2007) A recurrent in-frame insertion in a CEBPA transactivation domain is a polymorphism rather than a mutation that does not affect gene expression profiling-based clustering of AML. Blood 109(1):389–390CrossRefPubMed Wouters BJ, Louwers I, Valk PJ, Lowenberg B, Delwel R (2007) A recurrent in-frame insertion in a CEBPA transactivation domain is a polymorphism rather than a mutation that does not affect gene expression profiling-based clustering of AML. Blood 109(1):389–390CrossRefPubMed
16.
go back to reference Fröhling S, Corbacioglu A, Schlenk R, Döhner H, Döhner K (2007) In reply. J Clin Oncol 25(17):2494–2495CrossRef Fröhling S, Corbacioglu A, Schlenk R, Döhner H, Döhner K (2007) In reply. J Clin Oncol 25(17):2494–2495CrossRef
Metadata
Title
Molecular study of CEPBA in familial hematological malignancies
Authors
R. El Abed
V. Bourdon
L. Huiart
F. Eisinger
A. Khelif
M. Frenay
P. Gesta
L. Demange
H. Dreyfus
V. Bonadona
C. Dugast
H. Zattara
L. Faivre
T. Noguchi
R. Sauvan
Z. Soua
H. Sobol
Publication date
01-12-2009
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 4/2009
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-009-9289-x

Other articles of this Issue 4/2009

Familial Cancer 4/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine